BRAF and thyroid cancer, nonmedullary, 2: This divergence underscores a critical diagnostic limitation of a BRAF-only approach, which will inevitably miss a significant proportion of FVPTCs and other RAS-driven entities like follicular thyroid carcinoma (FTC).